转诊之外:重构美国肾移植流程以促进公平可及
本文指出仅增加肾移植转诊可能加剧下游评估资源压力,因供肾稀缺,更多转诊未必转化为移植。作者呼吁在移植前系统的多个层面进行紧急重新评估与设计,以实现终末期肾病患者公平获得肾移植。
要点
- 仅增加转诊可能将系统压力与不平等传递至下游评估流程
- 移植前评估对患者、家庭、移植中心及支付方均资源密集
- 需在移植前系统多层面重新设计以促进公平可及
核心结论
- 仅增加转诊不足以改善肾移植公平可及,需同步重构移植前评估与支持系统。
主要发现
- 供肾稀缺背景下,转诊增加可能导致更多患者完成评估却未获移植。
- 转诊与评估过程对患者、家庭、移植项目及支付方均高度资源密集。
- 患者可能承担自付费用及非 routine 诊疗所需的检查与治疗。
- 移植项目可能面临容量不足、流程低效与财务挑战。
- 孤立增加转诊可能将系统压力与差异传递至下游流程。
临床怎么用
- 肾内科医生在推动转诊时应同步关注评估流程的资源与公平性。
- 移植中心需优化评估容量与工作流程以承接增加的转诊。
- 政策制定者应支持移植前系统多层面重新设计而非仅扩大转诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advocates for improved equity in kidney transplants in the United States have recently focused their efforts on initiatives to increase referral for transplant evaluation. However, because donor kidneys remain scarce, increased referrals are likely to result in an increasing number of patients proceeding through the evaluation process without ultimately receiving a kidney. Unfortunately, the process of referral and evaluation can be highly resource-intensive for patients, families, transplant programs, and payers. Patients and families may incur out-of-pocket expenses and be required to complete testing and treatments that they might not have chosen in the course of routine clinical care. Kidney transplant programs may struggle with insufficient capacity, inefficient workflow, and challenging programmatic finances, and payers will need to absorb the increased expenses of upfront pretransplant costs. Increased referral in isolation may risk simply transmitting system stress and resulting disparities to downstream processes in this complex system. We argue that success in efforts to improve access through increased referrals hinges on adaptations to the pretransplant process more broadly. We call for an urgent re-evaluation and redesign at multiple levels of the pretransplant system in order to achieve the aim of equitable access to kidney transplantation for all patients with kidney failure.
引用
- Butler CR, Reese PP, Cheng XS, et al. Referral and Beyond: Restructuring the Kidney Transplant Process to Support Greater Access in the United States. Am J Kidney Dis. 2024. PMID: 38670253. doi:10.1053/j.ajkd.2024.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。